Hospital
Sacred Heart Health System, INC.
Sacred Heart Health System, INC. was paid $38.49M by Medicaid between Jan 2018 and Dec 2024, across 507 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoSACRED HEART HEALTH SYSTEM, INC.
PENSACOLA, FL 32504
PENSACOLA, FL 32504
33aNPI1922032424assigned 07/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$38.49M
24GClaims1,875,217
24DCodes billed507
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#3 of 163
Median peer was paid$4.77M
This provider vs. median8.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 141,478 | $2.64M | |
| 2019 | 353,794 | $5.60M | |
| 2020 | 342,738 | $5.45M | |
| 2021 | 409,901 | $7.43M | |
| 2022 | 408,034 | $9.31M | |
| 2023 | 169,932 | $5.43M | |
| 2024incomplete | 49,340 | $2.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 88,504 | 80,262 | $7.01M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 43,550 | 38,521 | $4.06M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.6% | 29,202 | 23,836 | $2.53M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 4.0% | 14,989 | 4,694 | $1.55M |
| 36415 | Collection of venous blood by venipuncture | 3.3% | 73,366 | 56,209 | $1.26M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.7% | 23,708 | 7,436 | $1.03M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.7% | 23,675 | 6,672 | $1.02M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.5% | 15,120 | 10,266 | $960K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.5% | 2,621 | 2,220 | $948K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 9,994 | 9,451 | $833K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 8,625 | 5,589 | $717K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 23,211 | 15,255 | $642K |
495 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 15,627 | $617K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.6% | 10,721 | $601K |
| 81001 | 1.5% | 52,592 | $566K | |
| 96367 | 1.5% | 6,008 | $565K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 5,420 | $490K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 4,649 | $408K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.0% | 11,815 | $389K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 118,606 | $366K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 931 | $332K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 25,437 | $332K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,686 | $314K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 658 | $286K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,455 | $243K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,692 | $235K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,725 | $230K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 20,221 | $229K |
| 80053 | Comprehensive metabolic panel | <1% | 73,179 | $228K |
| 97010 | <1% | 6,211 | $226K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 31,211 | $218K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,783 | $209K |
| 87486 | <1% | 10,766 | $200K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,492 | $188K |
| 95782 | <1% | 403 | $179K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,677 | $173K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,593 | $168K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,726 | $160K |
| 01999 | <1% | 14,337 | $159K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,554 | $155K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 8,717 | $152K |
| 76770 | <1% | 2,056 | $138K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 39,929 | $137K |
| 97162 | <1% | 2,192 | $137K | |
| 96415 | <1% | 2,573 | $135K | |
| 97161 | <1% | 1,679 | $135K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 18,525 | $121K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,473 | $117K |
| 77386 | <1% | 863 | $117K | |
| A9270 | Non-covered item or service | <1% | 33,730 | $117K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,883 | $115K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,538 | $108K |
| 54161 | <1% | 124 | $102K | |
| 42830 | <1% | 256 | $101K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 67 | $101K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 698 | $95K |
| 36430 | <1% | 1,443 | $92K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,436 | $92K |
| 82728 | <1% | 7,358 | $88K | |
| 59025 | Fetal non-stress test | <1% | 2,670 | $88K |
| 77336 | <1% | 612 | $82K | |
| 87081 | <1% | 4,267 | $81K | |
| 92523 | <1% | 1,170 | $79K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,170 | $75K |
| 82962 | <1% | 12,637 | $72K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30,428 | $71K |
| G0378 | Hospital observation service, per hour | <1% | 9,102 | $71K |
| 74018 | <1% | 3,764 | $70K | |
| 80074 | <1% | 1,773 | $70K | |
| 80076 | <1% | 11,109 | $63K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,344 | $62K |
| 83615 | <1% | 6,222 | $62K | |
| 83735 | <1% | 17,746 | $59K | |
| 97016 | <1% | 2,064 | $59K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,276 | $59K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 14,157 | $58K |
| 97165 | <1% | 724 | $56K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 19,186 | $56K |
| 87070 | <1% | 3,916 | $53K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,699 | $52K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 853 | $52K |
| 72141 | <1% | 620 | $52K | |
| C1769 | Guide wire | <1% | 1,795 | $51K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,400 | $49K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,394 | $49K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 447 | $49K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,843 | $49K |
| 97163 | <1% | 555 | $48K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,084 | $47K |
| 84439 | <1% | 7,528 | $47K | |
| 87653 | <1% | 3,170 | $47K | |
| 86850 | <1% | 7,875 | $46K | |
| 99234 | <1% | 7,737 | $45K | |
| 97597 | <1% | 780 | $44K | |
| 70486 | <1% | 840 | $43K | |
| 74019 | <1% | 4,622 | $43K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,228 | $43K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,117 | $42K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,835 | $41K |
| 73610 | <1% | 2,374 | $41K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 300 | $41K |
| 95819 | <1% | 404 | $39K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,026 | $37K |
| 76536 | <1% | 848 | $37K | |
| 12011 | <1% | 679 | $37K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 616 | $37K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 16,719 | $36K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,350 | $36K |
| 82378 | <1% | 2,446 | $36K | |
| 73564 | <1% | 3,036 | $35K | |
| 97168 | <1% | 401 | $35K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 480 | $34K |
| 95886 | <1% | 380 | $34K | |
| 86140 | <1% | 8,800 | $33K | |
| 76642 | <1% | 1,034 | $32K | |
| 36591 | <1% | 6,688 | $31K | |
| 73630 | <1% | 2,825 | $31K | |
| 95700 | <1% | 213 | $30K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,603 | $30K |
| 87210 | <1% | 5,888 | $30K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 16,751 | $30K |
| 96376 | <1% | 6,019 | $29K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 11,153 | $29K |
| 73030 | <1% | 2,393 | $28K | |
| 93971 | <1% | 1,444 | $28K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,120 | $27K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,047 | $27K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,854 | $27K |
| 73130 | <1% | 1,897 | $27K | |
| 85027 | <1% | 9,704 | $27K | |
| 12001 | <1% | 477 | $27K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 753 | $26K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,619 | $26K |
| 92526 | <1% | 1,415 | $26K | |
| 76820 | <1% | 472 | $25K | |
| 73140 | <1% | 878 | $25K | |
| 93975 | <1% | 1,445 | $25K | |
| 84484 | <1% | 14,093 | $24K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,198 | $24K |
| 82330 | <1% | 2,370 | $24K | |
| 73110 | <1% | 1,447 | $24K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,507 | $24K |
| J2704 | Injection, propofol, 10 mg | <1% | 14,222 | $24K |
| 87077 | <1% | 8,787 | $23K | |
| 85610 | <1% | 10,082 | $23K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,349 | $23K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 5,642 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,458 | $23K |
| 83880 | <1% | 5,496 | $23K | |
| 84703 | <1% | 11,420 | $23K | |
| 85730 | <1% | 7,456 | $22K | |
| 83690 | <1% | 12,341 | $22K | |
| 72100 | <1% | 1,790 | $22K | |
| 76801 | <1% | 1,906 | $22K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,381 | $21K |
| 82607 | <1% | 5,257 | $21K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 158 | $21K |
| 83970 | <1% | 1,712 | $20K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,411 | $20K |
| 87634 | <1% | 1,603 | $19K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,346 | $19K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,802 | $19K |
| 96416 | <1% | 832 | $18K | |
| 86900 | <1% | 10,420 | $18K | |
| 84702 | <1% | 5,821 | $18K | |
| J3490 | Unclassified drugs | <1% | 5,740 | $18K |
| 36561 | <1% | 53 | $18K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 4,061 | $18K |
| 76830 | Ultrasound, transvaginal | <1% | 1,217 | $17K |
| 71250 | <1% | 721 | $17K | |
| 97164 | <1% | 402 | $16K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,794 | $15K |
| J0897 | Injection, denosumab, 1 mg | <1% | 267 | $15K |
| 77412 | <1% | 90 | $15K | |
| 72110 | <1% | 1,017 | $15K | |
| 96523 | <1% | 1,786 | $15K | |
| 81025 | <1% | 3,481 | $15K | |
| 84436 | <1% | 635 | $15K | |
| 76870 | <1% | 425 | $14K | |
| 72040 | <1% | 776 | $14K | |
| 77066 | Tomosynthesis, mammo | <1% | 393 | $14K |
| 82550 | <1% | 3,299 | $14K | |
| 95816 | <1% | 93 | $13K | |
| 82553 | <1% | 1,582 | $13K | |
| 73090 | <1% | 1,027 | $13K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,782 | $13K |
| 99152 | <1% | 1,502 | $13K | |
| 84100 | <1% | 7,001 | $13K | |
| 84112 | <1% | 1,088 | $13K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,357 | $12K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,154 | $12K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,060 | $12K |
| 85652 | <1% | 5,103 | $12K | |
| 97166 | <1% | 221 | $12K | |
| 73502 | <1% | 1,791 | $12K | |
| 82570 | <1% | 6,320 | $12K | |
| 70491 | <1% | 142 | $12K | |
| 87186 | <1% | 5,955 | $12K | |
| 86592 | <1% | 6,185 | $12K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,407 | $12K |
| 96411 | <1% | 1,834 | $11K | |
| 70360 | <1% | 412 | $11K | |
| 93017 | <1% | 545 | $11K | |
| 73080 | <1% | 737 | $11K | |
| 92610 | <1% | 198 | $11K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,227 | $10K |
| 82565 | <1% | 2,970 | $10K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,076 | $10K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,598 | $10K |
| 72050 | <1% | 382 | $9K | |
| 82950 | <1% | 1,616 | $9K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,182 | $9K |
| 96368 | <1% | 1,268 | $9K | |
| 97116 | <1% | 1,277 | $9K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 584 | $9K |
| 86901 | <1% | 10,483 | $9K | |
| 73590 | <1% | 1,120 | $9K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 760 | $9K |
| 83540 | <1% | 5,519 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,570 | $9K |
| 82784 | <1% | 1,885 | $8K | |
| 96417 | <1% | 2,857 | $8K | |
| 87040 | <1% | 5,627 | $8K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 517 | $8K |
| 77300 | <1% | 68 | $8K | |
| 96521 | <1% | 329 | $8K | |
| 80061 | Lipid panel | <1% | 9,561 | $8K |
| 93970 | <1% | 436 | $8K | |
| 73562 | <1% | 656 | $8K | |
| 82375 | <1% | 2,521 | $7K | |
| 82805 | <1% | 2,462 | $7K | |
| 72082 | <1% | 228 | $7K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 218 | $7K |
| 83605 | <1% | 4,381 | $7K | |
| 85045 | <1% | 4,290 | $7K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 731 | $7K |
| 87340 | <1% | 5,203 | $7K | |
| 82248 | <1% | 2,300 | $6K | |
| 87045 | <1% | 544 | $6K | |
| 82731 | <1% | 519 | $6K | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 789 | $6K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,487 | $6K |
| 83050 | <1% | 2,531 | $6K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,294 | $6K |
| 86803 | <1% | 4,724 | $6K | |
| 10060 | <1% | 185 | $6K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 326 | $5K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,450 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,662 | $5K |
| 86304 | <1% | 648 | $5K | |
| 86003 | <1% | 1,288 | $5K | |
| 97035 | <1% | 294 | $5K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 360 | $5K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,232 | $5K |
| 73560 | <1% | 377 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,052 | $5K |
| 82746 | <1% | 3,244 | $5K | |
| 87205 | <1% | 3,346 | $5K | |
| 86644 | <1% | 85 | $5K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 206 | $5K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 2,642 | $4K |
| 82150 | <1% | 2,075 | $4K | |
| 76000 | <1% | 724 | $4K | |
| 82247 | <1% | 1,701 | $4K | |
| 94060 | <1% | 84 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 6,924 | $4K |
| 74230 | <1% | 54 | $4K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,540 | $4K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 722 | $4K |
| 77072 | <1% | 76 | $4K | |
| 84550 | <1% | 3,249 | $4K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 850 | $4K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 130 | $4K |
| 70250 | <1% | 118 | $4K | |
| 76882 | <1% | 107 | $3K | |
| 84466 | <1% | 4,650 | $3K | |
| 84146 | <1% | 377 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,921 | $3K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 2,905 | $3K |
| 87581 | <1% | 10,770 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 90 | $3K |
| 81003 | <1% | 1,191 | $3K | |
| 96409 | <1% | 421 | $3K | |
| 85379 | <1% | 1,895 | $3K | |
| 87075 | <1% | 1,725 | $3K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 45 | $3K |
| 72131 | <1% | 162 | $3K | |
| 82785 | <1% | 997 | $3K | |
| 74022 | <1% | 580 | $3K | |
| 95910 | <1% | 56 | $3K | |
| 73552 | <1% | 398 | $3K | |
| 95711 | <1% | 42 | $2K | |
| 83516 | <1% | 1,587 | $2K | |
| 83655 | <1% | 693 | $2K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 37 | $2K |
| 80197 | <1% | 1,686 | $2K | |
| 76937 | <1% | 376 | $2K | |
| 84156 | <1% | 4,824 | $2K | |
| 54300 | <1% | 13 | $2K | |
| 78264 | <1% | 15 | $2K | |
| 86762 | <1% | 3,447 | $2K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 96 | $2K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,121 | $2K |
| 12002 | <1% | 48 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 89 | $2K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 181 | $2K |
| 83550 | <1% | 4,028 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 49 | $2K |
| 72146 | <1% | 12 | $2K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 2,200 | $2K |
| 86301 | <1% | 340 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,556 | $2K |
| 99217 | <1% | 91 | $2K | |
| 72070 | <1% | 210 | $2K | |
| 83020 | <1% | 1,991 | $2K | |
| 84153 | <1% | 244 | $2K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,295 | $2K |
| 29125 | <1% | 453 | $2K | |
| 82140 | <1% | 634 | $2K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,167 | $2K |
| 87015 | <1% | 138 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 424 | $2K |
| 3044F | <1% | 51 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 73 | $2K |
| 86300 | <1% | 856 | $2K | |
| 90715 | <1% | 1,319 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,542 | $1K |
| 86923 | <1% | 774 | $1K | |
| 80320 | <1% | 338 | $1K | |
| 93880 | <1% | 80 | $1K | |
| 82043 | <1% | 1,458 | $1K | |
| 83520 | <1% | 482 | $1K | |
| 82951 | <1% | 921 | $1K | |
| 99218 | <1% | 32 | $1K | |
| 77080 | <1% | 284 | $1K | |
| 72156 | <1% | 26 | $1K | |
| 84155 | <1% | 656 | $1K | |
| 80164 | <1% | 124 | $1K | |
| 84165 | <1% | 933 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,169 | $1K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 751 | $1K |
| 80069 | <1% | 423 | $1K | |
| 82435 | <1% | 1,242 | $1K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 375 | $1K |
| 95911 | <1% | 13 | $1K | |
| 74240 | <1% | 28 | $995.60 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 277 | $968.22 |
| 84481 | <1% | 452 | $960.41 | |
| 86706 | <1% | 1,635 | $959.81 | |
| 77334 | <1% | 27 | $934.65 | |
| 93325 | <1% | 12 | $906.71 | |
| 77001 | <1% | 87 | $902.91 | |
| 71101 | <1% | 47 | $876.89 | |
| 73620 | <1% | 61 | $861.60 | |
| 97167 | <1% | 14 | $854.60 | |
| 85384 | <1% | 187 | $823.69 | |
| 86695 | <1% | 1,367 | $778.41 | |
| 86920 | <1% | 169 | $747.26 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 256 | $742.14 |
| 88321 | <1% | 141 | $729.58 | |
| 20610 | <1% | 183 | $725.98 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 268 | $720.70 |
| 70496 | <1% | 16 | $688.29 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 182 | $685.06 |
| 82670 | <1% | 134 | $681.51 | |
| 84480 | <1% | 113 | $675.91 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 353 | $675.62 |
| 86038 | <1% | 879 | $664.04 | |
| 76825 | <1% | 12 | $662.09 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 251 | $633.62 |
| 86694 | <1% | 461 | $612.10 | |
| 83001 | <1% | 443 | $605.44 | |
| 96402 | <1% | 58 | $601.34 | |
| 87536 | <1% | 29 | $594.62 | |
| 86001 | <1% | 796 | $583.91 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 814 | $578.61 |
| 73660 | <1% | 14 | $574.65 | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 134 | $564.73 |
| 84132 | <1% | 1,533 | $564.12 | |
| 86431 | <1% | 451 | $498.93 | |
| 87641 | <1% | 139 | $498.72 | |
| 84681 | <1% | 117 | $491.34 | |
| 84403 | <1% | 449 | $469.48 | |
| 82105 | <1% | 113 | $467.57 | |
| 93296 | <1% | 328 | $449.65 | |
| 85660 | <1% | 79 | $445.41 | |
| 82947 | <1% | 1,381 | $432.88 | |
| 85018 | <1% | 1,426 | $428.21 | |
| 76827 | <1% | 12 | $417.63 | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 14 | $398.22 |
| 89051 | <1% | 205 | $386.65 | |
| 76775 | <1% | 14 | $373.39 | |
| 93270 | <1% | 29 | $371.00 | |
| 86696 | <1% | 1,367 | $363.98 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 907 | $340.78 |
| 72170 | <1% | 55 | $323.18 | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 258 | $313.10 |
| 74241 | <1% | 15 | $309.48 | |
| 84520 | <1% | 399 | $295.50 | |
| 80177 | <1% | 100 | $291.12 | |
| 94664 | <1% | 189 | $282.12 | |
| 86320 | <1% | 272 | $281.57 | |
| 86902 | <1% | 65 | $278.18 | |
| Q3014 | Telehealth originating site facility fee | <1% | 470 | $250.63 |
| 87529 | <1% | 83 | $248.50 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 231 | $228.97 |
| 88184 | <1% | 20 | $228.47 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 233 | $219.42 |
| 82977 | <1% | 628 | $214.12 | |
| 82533 | <1% | 65 | $206.34 | |
| 86704 | <1% | 445 | $196.96 | |
| 87046 | <1% | 564 | $194.78 | |
| 82010 | <1% | 93 | $187.87 | |
| 83002 | <1% | 284 | $184.17 | |
| 84295 | <1% | 1,194 | $180.74 | |
| G0008 | Administration of influenza virus vaccine | <1% | 662 | $174.66 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 250 | $168.75 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 23 | $168.74 |
| 94762 | <1% | 495 | $164.53 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 46 | $136.68 |
| 87147 | <1% | 411 | $129.78 | |
| 73521 | <1% | 14 | $128.70 | |
| 73060 | <1% | 95 | $124.19 | |
| 86709 | <1% | 411 | $118.95 | |
| 86780 | <1% | 470 | $114.55 | |
| 80202 | <1% | 33 | $113.59 | |
| 96401 | <1% | 54 | $110.24 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 39 | $109.96 |
| 86665 | <1% | 13 | $107.86 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 364 | $103.03 |
| 88230 | <1% | 12 | $102.39 | |
| 87177 | <1% | 151 | $100.96 | |
| 83525 | <1% | 156 | $91.32 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 27 | $90.00 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 155 | $87.34 |
| 86787 | <1% | 85 | $78.86 | |
| 86922 | <1% | 78 | $78.66 | |
| 97022 | <1% | 52 | $78.37 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 346 | $77.47 |
| 76010 | <1% | 26 | $73.54 | |
| 94727 | <1% | 52 | $68.77 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 65 | $54.67 |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 130 | $50.10 |
| 86308 | <1% | 71 | $47.17 | |
| 92611 | <1% | 25 | $38.77 | |
| 83993 | <1% | 15 | $38.12 | |
| 87899 | <1% | 1,022 | $37.81 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 69 | $36.91 |
| 82274 | <1% | 31 | $34.20 | |
| 87640 | <1% | 32 | $32.22 | |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | <1% | 33 | $30.81 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 163 | $30.42 |
| 85007 | <1% | 96 | $29.42 | |
| 86800 | <1% | 46 | $25.30 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,532 | $20.02 |
| 87209 | <1% | 151 | $19.10 | |
| 86376 | <1% | 168 | $18.34 | |
| 88342 | <1% | 31 | $13.64 | |
| 86141 | <1% | 40 | $13.63 | |
| 88185 | <1% | 36 | $12.48 | |
| 90686 | <1% | 223 | $12.01 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 30 | $11.45 |
| 84145 | <1% | 386 | $7.68 | |
| 84270 | <1% | 40 | $6.75 | |
| 82040 | <1% | 29 | $6.30 | |
| 86708 | <1% | 15 | $5.42 | |
| 87324 | <1% | 27 | $4.64 | |
| 84450 | <1% | 131 | $3.85 | |
| 86645 | <1% | 12 | $3.30 | |
| 82310 | <1% | 34 | $3.15 | |
| 84460 | <1% | 113 | $2.37 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 47 | $2.37 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 26 | $2.37 |
| 94729 | <1% | 54 | $1.90 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 28 | $0.00 |
| 84305 | 0% | 26 | $0.00 | |
| 29505 | 0% | 33 | $0.00 | |
| 87076 | 0% | 16 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 220 | $0.00 |
| 90662 | 0% | 130 | $0.00 | |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | 0% | 60 | $0.00 |
| 85460 | 0% | 27 | $0.00 | |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | 0% | 30 | $0.00 |
| 36600 | 0% | 34 | $0.00 | |
| 86663 | 0% | 13 | $0.00 | |
| 88262 | 0% | 12 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 13 | $0.00 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 12 | $0.00 |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 0% | 22 | $0.00 |
| 85060 | 0% | 12 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 220 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 157 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 43 | $0.00 |
| 88291 | 0% | 12 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 17 | $0.00 |
| 84134 | 0% | 17 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 29 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 31 | $0.00 |
| 88304 | 0% | 16 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 25 | $0.00 |
| 90674 | 0% | 18 | $0.00 | |
| Q2035 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria) | 0% | 14 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 13 | $0.00 |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 21 | $0.00 |
| 82952 | 0% | 14 | $0.00 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | 0% | 12 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCORNEJO, COBA (COO)
Parent organizationSACRED HEART HEALTH SYSTEM, INC.
| Provider | Location | Paid |
|---|---|---|
| Ascension Sacred Heart Emerald Coast | Miramar Beach, FL | $11.93M |
| Ascension Sacred Heart Gulf | Port St Joe, FL | $2.50M |
| ST Vincents Health System INC | St. Johns, FL | $24K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.